Longeveron receives notice of allowance from USPTO for tech behind Lomecel-B

Longeveron announces it received a notice of patent allowance from the United States Patent and Trademark Office, USPTO, for Medicinal Signaling Cells, MSCs, the technology, tech, behind its lead investigational product Lomecel-B. The allowance impacts patients with Aging-related Frailty receiving vaccines for conditions such as Covid and the flu. The new U.S. patent adds to the intellectual property from previous patents issued to Longeveron in the European Union and Japan. Longeveron currently is conducting a trial of Aging-related Frailty in Japan aligned with the Japan Pharmaceuticals and Medical Devices Agency. The Phase 2 trial design is intended to provide support for a limited approval under Japan’s Act on the Safety of Regenerative Medicine. The patent allowance claims relate to the use of MSCs to enhance an immune response to a vaccine, or to induce an immune response, in patients with Aging-related Frailty whose immune system did not previously react to the vaccines. “These newly allowed claims extend our patent estate to include the use of Lomecel-B in conjunction with or after patients receive vaccines to enhance vaccine immune response,” said inventor Joshua M. Hare, M.D., FACC, FAHA, Co-Founder and Chief Scientific Officer and Chairman of Longeveron. “We believe this use for Lomecel-B and the broader potential it holds for patients in our current Aging-related Frailty and Alzheimer’s disease trials reflects the broader potential of Lomecel-B.”